On 5 February 2024, Novo Nordisk’s parent company Novo Holdings announced that it will acquire global contract development and manufacture company Catalent for USD $16.5B.
Novo Holdings will secure 50 global sites in the acquisition and intends to sell three fill-finish sites and related assets (located in Italy, USA and Belgium) to Novo Nordisk. The acquisition is expected to close towards the end of calendar year 2024.
This news follows the release on 31 January 2024 by Novo Nordisk of its 2023 Annual Report, where it presented an increase in sales by 31% to DKK 232.3B in 2023, representing an increase in its operating profit by 37%.